MarketCap
Facebook
X
TelegramQuarterly report 2024-Q1
added 05-06-2024
ShockWave Medical Cost of Revenue 2011-2026 | SWAV
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue ShockWave Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 95.4 M | 65 M | 41.4 M | 21 M | 17.2 M | 7.25 M | 2.84 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 95.4 M | 2.84 M | 35.7 M |
Quarterly Cost of Revenue ShockWave Medical
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.2 M | 24.5 M | 24.5 M | 21.1 M | - | 17.9 M | 16.7 M | 12.9 M | - | 10.9 M | 9.93 M | 7.89 M | - | 5.28 M | 3.59 M | 5.65 M | - | 4.4 M | 4.13 M | 3.07 M | - | 1.97 M | 1.18 M | 794 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.2 M | 794 K | 10.8 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
1.2 B | $ 176.83 | 5.97 % | $ 13.2 B |  USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 11.66 | 5.71 % | $ 1.75 B | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 34.0 | 9.71 % | $ 1.57 B | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 12.18 | 2.01 % | $ 1.65 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 281.15 | 1.13 % | $ 7.93 B | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.62 | 1.67 % | $ 38.6 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 38.25 | 4.31 % | $ 5.7 K | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 62.56 | 1.15 % | $ 92.6 B | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Electromed
ELMD
|
14 M | $ 24.4 | 2.61 % | $ 206 M | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 9.17 | 1.1 % | $ 260 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
958 M | $ 91.96 | 2.13 % | $ 12.4 B | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Inogen
INGN
|
194 M | $ 6.67 | -1.91 % | $ 177 M | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 53.38 | -1.89 % | $ 1.57 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.03 | - | $ 17.4 M | USA |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 87.48 | 2.78 % | $ 3.04 B | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 16.01 | 1.59 % | $ 376 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
LivaNova PLC
LIVN
|
448 M | $ 64.66 | 1.76 % | $ 3.53 B |  Britain |
 |
LENSAR
LNSR
|
31.3 M | $ 5.53 | -1.78 % | $ 66.1 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.14 | 2.22 % | $ 876 M | USA |
 |
EDAP TMS S.A.
EDAP
|
36 M | $ 3.37 | -0.88 % | $ 126 M |  France |
 |
Myomo
MYO
|
14 M | $ 0.68 | 0.44 % | $ 28.5 M | USA |
 |
NanoVibronix
NAOV
|
1.05 M | - | - | $ 1.08 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 9.85 | 1.86 % | $ 353 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Natus Medical Incorporated
NTUS
|
197 M | - | 1.94 % | $ 1.05 B | USA |
 |
Nevro Corp.
NVRO
|
139 M | - | - | $ 217 M | USA |